Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

[News]

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

More... (http://www.news-medical.net/news/20101118/Exelixis-reports-interim-data-from-phase-2-RDT-trial-for-epithelial-ovarian-cancer.aspx)